FACIT announced the addition of an Investment and Asset Management Committee to provide strategic and expert advice on investment opportunities and support the growth and performance of its asset portfolio.
FACIT is a commercialization venture firm focused on Ontario-based oncology start-ups. To date, the company’s portfolio has attracted more than $1.7 billion in follow-on investment and generated local economic value through 11 successful exits, the formation of 20 new start-ups, and support for 17 first-in-human clinical studies.
The committee will be led by inaugural Chair Dr. Elizabeth Douville, Vice-President, Corporate Development at Biologics Manufacturing Centre. The other committee members include Kelly Holman, Co-Founder and Managing Director of Genesys Capital; Ken Newport, Co-Founder and Executive Chairman of Virica Biotech; and Dr. Tom Hudson, Venture Partner at Versant Ventures and former President and Scientific Director of the Ontario Institute for Cancer Research.
FACIT said it will draw on the committee’s health-sector expertise and investor experience to advise on strategic investment opportunities arising from Ontario’s research institutions and cancer start-ups. The committee will also support FACIT’s efforts to continue scaling companies, creating jobs, and advancing cancer innovations toward patient benefit.
FACIT makes venture investments through its Compass Rose Oncology Fund, which is designed to capitalize on Ontario’s research strengths and advance cancer care. Unlike traditional venture capital funds, FACIT’s investment model balances economic value creation with potential healthcare impact.
The company also reinvests proceeds from investment returns into future Ontario innovation opportunities, creating a cycle intended to multiply the value of invested capital. The Compass Rose Fund is part of FACIT’s broader continuum of commercialization capital and entrepreneurial support programs, with a focus on pre-seed and seed-stage ventures.
FACIT said the addition of the committee will further strengthen its advisory support for start-up management teams as they navigate financing, commercialization, and growth challenges.
KEY QUOTES:
“This Investment Committee represents an important step in FACIT’s strategy to help unlock the full value and potential of Ontario innovations. Its guidance will be invaluable as we accelerate the development of cancer solutions that deliver meaningful impact for patients and the local economy.”
Susan Fitzpatrick, Chair of FACIT’s Board of Directors
“FACIT has built a distinctive commercialization model supporting high-potential oncology ventures and creating long-term value for Ontario’s healthcare and life sciences ecosystems. I look forward to working with my fellow Committee members and the FACIT team to continue strengthening the portfolio and help position companies to successfully attract and secure additional capital.”
Dr. Elizabeth Douville, Vice-President, Corporate Development at Biologics Manufacturing Centre
